Author Archives: admin


Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder – Newswise

Newswise Massachusetts Eye and Ear, a member hospital of Mass General Brigham, is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa.

Inherited retinal degenerations (IRDs), such as retinitis pigmentosa, are a group of blinding eye diseases caused by mutations in over 270 different genes. Mutations in the PRPF31 gene are the second most common cause of dominant IRD and lead to defects in the function of the retinal pigment epithelial (RPE) cells and photoreceptors of the retina. Previous lab-based research performed by members of the Ocular Genomics Institute at Harvard Ophthalmology, led by Eric A. Pierce, MD, PhD, demonstrated that adeno-associated virus (AAV)-mediated gene augmentation therapy for PRPF31 can restore normal function to PRPF31 mutant RPE cells.

Biogen (Nasdaq: BIIB), a biopharmaceutical company that discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies, will build upon this prior work, and conduct the studies needed for clinical development of PRPF31 gene therapy. This includes the pre-clinical studies needed to support progression to clinical trials of PRPF31 gene therapy. As part of the agreement, Biogen will receive an exclusive license to develop the product worldwide and will be responsible for all U.S. Food and Drug-Administration (FDA) required investigational new drug (IND) enabling studies, clinical development and commercialization.

The treatment of IRDs with highly effective AAV-based gene therapies is core to Biogens ophthalmology strategy, said Chris Henderson, Head of Research, Biogen. This agreement underscores our commitment to that strategy and builds off of our acquisition of Nightstar Therapeutics in 2019 and our active clinical trials of gene therapies for different genetic forms of IRD. We are excited to work with Massachusetts Eye and Ear and look forward to applying our preclinical and clinical experience to their leading PRPF31 program.

We are thrilled to work with Biogen, who will bring to this effort its deep experience with the clinical development process, as we work toward our goal of developing a gene therapy for people with PRPF31-related eye disease, added Dr. Pierce, who is the William F. Chatlos Professor of Ophthalmology at Harvard Medical School. My ultimate hope for patients with inherited retinal disorders due to mutations in PRPF31 is that a gene therapy will preserve and potentially restore some of their vision.

About the Ocular Genomics Institute

The Ocular Genomics Institute at Harvard Ophthalmology aims to translate genomic medicine into precision ophthalmic care for patients with inherited eye disorders. It is home to one of the leading centers for early-phase clinical trials of therapies for inherited retinal degenerations, with seven gene-based and one stem cell trial currently in progress. The group works in conjunction with other departments throughout Harvard Medical School and Mass. Eye and Ear, including the Bioinformatics Center and Grousbeck Gene Therapy Center.

Dr. Pierces lab, established in 2011, is dedicated to research in an effort to improve the understanding of the molecular bases of IRDs so that rational therapies can be developed for these diseases.

In 2018, Mass. Eye and Ear surgeons performed the first post-FDA approval gene therapy for patients with a form of inherited retinal blindness caused by mutations in the gene RPE65 by injecting an AAV-based drug treatment into a patients eye, which restored vision in a 13-year-old boy. This therapy, called Luxturna, is now being used to treat patients with RPE65-associated retinal degeneration around the world.

One of the exciting aspects of our collaboration with Biogen is that mutations in the PRPF31 gene affect approximately 10 to 20 times more people than mutations in the RPE65 gene, said Dr. Pierce. Success with PRPF31 gene therapy could provide visual benefit to more patients, which is our ultimate goal.

Mass. Eye and Ear was one of the first centers to offer life-changing gene therapies to patients with inherited retinal disease, and we are thrilled with this new opportunity to develop a translational retinal therapy that could help even more patients, said Joan W. Miller, MD, Chief of Ophthalmology at Mass. Eye and Ear, Massachusetts General Hospital, and Brigham and Womens Hospital, and Chair of Ophthalmology and the David Glendenning Cogan Professor of Ophthalmology at Harvard Medical School.

According to Chris Coburn, Chief Innovation Officer, Mass General Brigham, the collaboration with Biogen illustrates the importance of academia and industry teaming to solve problems for patients worldwide. We are eager to see this progress reach patients who are challenged by blinding, degenerative eye disease, said Coburn. We look forward to working with Biogen to advance this break-through innovation.

Patients with an inherited retinal disease require genetic testing prior to being considered for any gene therapy treatment.

About Massachusetts Eye and Ear

Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass. Eye and Ear specializes in ophthalmology (eye care) and otolaryngologyhead and neck surgery (ear, nose and throat care). Mass. Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass. Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 20192020 Best Hospitals Survey,U.S. News & World Reportranked Mass. Eye and Ear #4 in the nation for eye care and #2 for ear, nose and throat care.For more information about life-changing care and research at Mass. Eye and Ear, visit our blog,Focus, and follow us onInstagram,TwitterandFacebook.

About Harvard Medical School Department of Ophthalmology

The Harvard Medical SchoolDepartment of Ophthalmologyis one of the leading and largest academic departments of ophthalmology in the nation. Composed of nine affiliates (Massachusetts Eye and Ear, which is home to Schepens Eye Research Institute; Massachusetts General Hospital; Brigham and Womens Hospital; Boston Childrens Hospital; Beth Israel Deaconess Medical Center; Joslin Diabetes Center/Beetham Eye Institute; Veterans Affairs Boston Healthcare System; Veterans Affairs Maine Healthcare System; and Cambridge Health Alliance) and several international partners, the department draws upon the resources of a global team to pursue a singular goaleradicate blinding diseases so that all children born today will see throughout their lifetimes. Formally established in 1871, the department is committed to its three-fold mission of providing premier clinical care, conducting transformational research, and providing world-class training for tomorrows leaders in ophthalmology.

Continue reading here:
Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise

Canine Arthritis Treatment Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast-…

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc., Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc, among others. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Canine Arthritis Treatment Market is expected to exceed more than US$ 3.18 Billion by 2024 at a CAGR of 4.4% in the given forecast period.

Browse Full Report: https://www.marketresearchengine.com/canine-arthritis-treatment-market

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

The Canine Arthritis Treatment Market is segmented on the lines of its treatment type, route of administration, end users and regional. Basis of End-User is segmented into Veterinary Hospitals and Clinics, Retail Pharmacies, Drug Stores and E-commerce. Based on Treatment Type it covers Non-steroidal anti-inflammatory drugs, Opioids and Stem Cell Therapy. Based on route of administration it covers Oral and Injectable. The Canine Arthritis Treatment Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

Reasons to Buy this Report:

1) Obtain the most up to date information available on all Canine Arthritis Treatment Market.

2) Identify growth segments and opportunities in the industry.

3) Facilitate decision making on the basis of strong historic and forecast of Canine Arthritis Treatment Market.

4) Assess your competitors refining portfolio and its evolution.

Canine arthritis may be a chronic condition that ends up in inflammation of 1 or a lot of joints and progresses over time if left untreated. the foremost usually affected joints embody the knee, elbow, shoulder, hip and back. There are numerous causes of inflammatory disease in dogs like traumatic injuries, obesity, failure of correct bone development and lots of others. There are many sorts of canine arthritis however the foremost common is arthritis. It affects one in five adult dogs. The prevalence of arthritis will increase with the age of canines. Its a chronic disease characterised by the loss of gristle. It conjointly includes alternative abnormalities like osteophytotic in response to inflammation and pain.

The Canine Arthritis Treatment Market has been segmented as below:

By Treatment Type:

By Route of Administration:

By End-User:

This report provides:

1) An overview of the global market for Canine Arthritis Treatment Market and related technologies. 2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024. 3) Identifications of new market opportunities and targeted promotional plans for Canine Arthritis Treatment Market.

4) Discussion of research and development, and the demand for new products and new applications. 5) Comprehensive company profiles of major players in the industry.

Report Scope:

The scope of the report includes a detailed study of Canine Arthritis Treatment Market with the reasons given for variations in the growth of the industry in certain regions.

Request Sample Report from here: https://www.marketresearchengine.com/canine-arthritis-treatment-market

Table of Contents

4.1 Introduction

4.2 Drivers

4.3 Restrains

4.4 Industry Trends

4.5 Porters Five Forces Analysis

10.1 Elanco (Eli Lilly and Company)

10.2 Norbrook Laboratories Limited

10.3 Aratana Therapeutics Inc.

10.4 Dechra Pharmaceuticals Plc

10.5 VetStem Biopharma

10.6 Zoetis Inc.

10.7 Vetoquinol S.A.

10.8 Boehringer Ingelheim

10.9 Bayer AG

Other Related Market Research Reports:

Cardiac Assist Devices Market is Supposed to Reach at a CAGR of 10.02% by 2024

Cardiac Rehabilitation Devices Market is Supposed to Reach US$ 170 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Go here to read the rest:
Canine Arthritis Treatment Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast-...

Global Microcarrier System Market to Record Significant Rise in Revenue Share Owing to the Augmenting Demand in COVID 19 Pandemic – 3rd Watch News

Microcarrier system offers a system matrix which would develops the growth of adherent cells in bioreactors. Microcarrier system is beneficial for a numerous of parameters such as better cell yields, large culture surface area, and also decrease the risk of contamination which will provide advantage to the growth of global microcarrier system market. A shrill trend in the application of microcarrier system is for treatment of wide conditions and cost-effective therapy which are propelling the growth of the microcarrier system market. Additionally microcarrier system market working on marketing strategies so that potential population can access to biopharmaceuticals.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/31443

The major driving factor for microcarrier system market is growing inclination towards research & development activities in cell therapy research as well as the favorable funding is anticipated to drive growth within the stem cell therapy sector. The emerging demand for microcarrier system market is largely arising from the increasing incidences of cancer. Growing demand for stem cell therapy coupled with growing adoption for cell-based vaccines will foster the microcarrier system market growth. The endlessly increasing cost-effective cell production for numerous stem cell therapies in large scale is fueling the demand for microcarrier system market. Moreover, the growing demand for detection of numerous other diseases for instance cancer and other hereditary diseases increases the probabilities for stem therapy techniques consequently increasing demand for microcarrier system market. As well as manufacturers are focusing on developing innovative techniques for stem cell therapy which will boost the growth of the microcarrier system market. However, limitations in the production of high-density cell culture can restrain the growth of microcarrier system market.

The global microcarrier system market is segmented on the basis of Product Type, Application, End User and Geography:

The global microcarrier system market is into initial stages attributed to focus on acclimatizing to the new technique in stem cell therapy and its innovation. Consequently, the microcarrier system is projected to demonstrate exponential growth potential for the treatment of cancer patient owing to a higher inclination towards cost-effective therapy cost. The major parameter in the microcarrier system market is concentrating on increased manufacturing efficacy with effective therapies to the patient. The increasing new applications in hereditary diseases are anticipated to offer growth opportunities for the microcarrier system market. However recent development in the growth of adherent cells can boost microcarrier system market, for instance in 2018, the newly designed system for the development of adherent cells on microcarriers and rapid process development of vaccines was launched by Sartorius Stedim Biotech (SSB) which is mini bioreactor vessel for ambr 250.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/31443

Geographically, the global microcarrier system market is segmented into regions such as Latin America, Europe, North America, South Asia, East Asia Middle East & Africa and Oceania. North America is projected to emerge as a prominent market in the global microcarrier system market due to favorable reimbursement scenarios and superior healthcare infrastructure. Increase in research funds which are provided by various biopharmaceutical companies will fuel the growth of global microcarrier system market in European countries like France, the UK, Spain, Germany, and others. The microcarrier system market in south Asia and East Asia is expected to grow substantially due to the high number of patient population and growing demand for cell-based vaccines. The Middle East and Africa (MEA) can make symbolic progress due to increasing investment in the Middle Eastern countries like Israel, Dubai, and others.

Some of the major key players competing in the global microcarrier system Market are General Electric Company, Thermo Fisher Scientific Inc., Lonza Group, Eppendorf, HiMedia Laboratories, Merck KGaA, Danaher Corporation, Becton, Dickinson and Company and Corning Incorporated, The Sartorius group and among others.

Continue reading here:
Global Microcarrier System Market to Record Significant Rise in Revenue Share Owing to the Augmenting Demand in COVID 19 Pandemic - 3rd Watch News

Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results – Business Wire

PHILADELPHIA--(BUSINESS WIRE)--Context Therapeutics LLC, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced that results from a safety review from preclinical and two Phase 1-2 studies evaluating its drug candidate onapristone extended release (ONA-ER) for the treatment of progesterone receptor (PR) positive cancers has been published in the journal Drug Safety. ONA-ER is an investigational, potentially best-in-class oral progesterone receptor (PR) antagonist. If approved, ONA-ER would be the first FDA-approved medication for PR+ cancers.

Antiprogestins demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone was previously evaluated in Phase 2 studies for metastatic breast cancer. Due to liver enzyme elevations identified during these studies, further development was halted. Evaluation of antiprogestin pharmacology and pharmacokinetic (PK) data suggests that liver enzyme elevations might be related to off-target effects associated with serum Cmax levels. If correct, this suggests the use of pharmaceutic strategies targeting efficacious systemic dose levels, but with a diminished Cmax. One such strategy twice-daily dosing of an extended release (ER) formulation of onapristone (ONA-ER) was developed and clinically evaluated in two phase 1-2 studies in PR-positive malignancies. In light of renewed interest in antiprogestin therapy for treating PR-positive breast and gynecologic cancer, the publication authors assessed the hepatotoxic potential of: (a) onapristone in liver-focused preclinical toxicology models, and (b) ONA-ER based on data from two phase 1-2 studies involving breast, ovarian, endometrial, and prostate cancer patients.

These results suggest that the extended-release formulation by reducing drug exposure may be associated with a reduced risk of hepatotoxicity, and supports the continued clinical evaluation of ONA-ER for treating PR-positive cancers, said study author James H. Lewis, MD, Director of Hepatology at MedStar Georgetown University Hospital.

In the Phase 1-2 trials, ONA-ER at escalating doses of 10 mg to 50 mg twice-a-day had a favorable safety and tolerability profile at all doses. There were no treatment-related severe adverse events among patients treated with ONA-ER. No clinical trial subject receiving ONA-ER developed liver test elevations meeting Hys Law criteria or other clinically significant hepatic injury considered to be drug-related.

Poor tolerability has limited the potential of antiprogestins for cancer patients, said Martin Lehr, Chief Executive Officer of Context. We are pleased with the results from this review, which highlight the potential of ONA-ER to meet a significant unmet need for a well tolerated treatment for PR-positive cancers.

About Onapristone ER

Onapristone ER (extended release) is a potent and specific antagonist of the progesterone receptor that is orally administered. Currently, there are no approved therapies that selectively target progesterone receptor (PR) positive cancers. Preclinical and clinical data suggest that onapristone ER has anticancer activity by inhibiting progesterone receptor binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion. Onapristone ER is currently being evaluated in patients with PR+ rare ovarian and endometrial cancers in the ongoing Phase 2 ONWARD 220 clinical trial. Additional Phase 2 clinical trials in ER+, PR+, HER2- breast cancer and PR-positive endometrial cancers will be initiated in 2020. Onapristone ER is an investigational drug that has not been approved for marketing by any regulatory authority.

About Context Therapeutics

Context Therapeutics LLC is a clinical-stage biopharmaceutical company advancing medicines to treat hormone driven cancers. Contexts lead program is onapristone ER, an investigational Phase 2 drug that is being developed for progesterone receptor positive breast, ovarian and endometrial cancers. For more information on Context, visit http://www.contexttherapeutics.com.

Here is the original post:
Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results - Business Wire

REGENERATIVE MEDICINE MARKET ALONG WITH COVID-19 IMPACT ANALYSIS AND CLINICAL OUTLOOK 2022 | STRYKER CORPORATION, ZIMMER BIOMET HOLDINGS INC.,…

The Global Regenerative Medicine Market research report offers an in-depth analysis of the global market, providing relevant information for the new market entrants or well-established players. Some of the key strategies employed by leading key players operating in the market and their impact analysis have been included in this research report. However, the small molecules & biologics segment is anticipated to grow at a highestCAGR of 34.2%from 2022,

Regenerative medicines hold the ability to replace, repair, and regenerate tissues and organs that are affected due to some disease, injury, or natural ageing process. These medicines are capable of restoring the functionality of tissues & cells applicable in a wide range of degenerative disorders such as neurodegenerative diseases, dermatology, cardiovascular and orthopedic applications. Researchers have been focusing on the development of advanced technologies based on genes, biologics, somatic cells and stem cells. Stem cells have the capability to proliferate and differentiate owing to which they are of importance in this field.

To get sample Copy @

https://www.reportsweb.com/inquiry&RW0001387617/sample

List of Top Key Players Profiled In The Report

Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic plc, Baxter International Inc., DePuy Synthes, Organogenesis Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Ocata Therapeutics Inc. (Astellas Pharma Inc.), CryoLife Inc.

The Regenerative Medicine Industry is extremely competitive and consolidated because of the existence of several established companies that are adopting different marketing strategies to increase their market share. The vendors engaged in the sector are outlined based on their geographic reach, financial performance, strategic moves, and product portfolio. The vendors are gradually widening their strategic moves, along with customer interaction.

The research on the Regenerative Medicine market concentrates on extracting valuable data on swelling investment pockets, significant growth opportunities, and major market vendors to help understand business owners what their competitors are doing best to stay ahead in the competition. The research also segments the Regenerative Medicine market on the basis of end user, product type, application, and demography for the forecast period 2020-2025.

To inquire about the discount available on this Report, visit @

https://www.reportsweb.com/inquiry&RW0001387617/discount

Regenerative Medicine market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America (SAM), which is later sub-segmented by respective countries and segments.

The key questions answered in the report:

-What will be the market size and growth rate in the 2020 year?

-What are the key factors driving the global Regenerative Medicine market?

-What are the risks and challenges in front of the market?

-Who are the key vendors in the global Regenerative Medicine market?

-Trending factors influencing the market shares of Regenerative Medicine?

-What are the key outcomes of Porters five forces model?

Access full Report Description, TOC, Table of Figure, Chart, etc. @

https://www.reportsweb.com/buy&RW0001387617/buy/4740

Table of Contents

Global Regenerative Medicine in 2020, by Manufacturers, Regions, Types and Applications

1 Study Coverage

2 Executive Summary

3 Market Size by Manufacturers

4 Production by Regions

5 Consumption by Regions

6 Market Size by Type

7 Market Size by Application

8 Manufacturers Profiles

9 Consumption Forecast

10 Upstream, Industry Chain and Downstream Customers Analysis

11 Opportunities & Challenges, Threat and Affecting Factors

Contact Us:

Name: Sameer Joshi

Email:[emailprotected]

Phone: +1-646-491-9876

About ReportsWeb:

ReportsWeb is a one stop shop of market research reports and solutions to various companies across the world. We help our clients in their decision support system by assisting them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

View original post here:
REGENERATIVE MEDICINE MARKET ALONG WITH COVID-19 IMPACT ANALYSIS AND CLINICAL OUTLOOK 2022 | STRYKER CORPORATION, ZIMMER BIOMET HOLDINGS INC.,...

Its not just the lungs: COVID-19 can affect the brain and heart of those infected, researchers say – WITI FOX 6 Milwaukee

LOS ANGELES As medical experts learn about the novel coronavirus, which continues to exhibit an array of ever-evolving symptoms and long-term effects, researchers have found that the deadly illness can have deleterious impacts on the heart and brain.

A recent study published on June 25 in the journalCell Reports Medicine, found that while COVID-19 is commonly known as a respiratory illness, the disease has also been known to instigate inflammatory responses in the body which can negatively affect the function of ones heart and brain.

According to the study, researchers observed SARS-CoV-2 infecting human heart cells that were grown from stem cells in a lab. Within 72 hours of infection, the virus managed to spread and replicate, killing the heart cells.

The researchers brought up the particularly alarming possibility that if COVID-19 can infect the heart cells in a laboratory setting, it could possibly infect those specific organs, prompting the need for a cardiac-specific antiviral drug screen program.

And those concerns are not unwarranted, according to doctors and other researchers who have been observing and studying the wide range of health problems and negative outcomes that appear to come with the not-yet-fully-known territory of the novel virus.

The most common coronavirus symptoms are fever, a dry cough and shortness of breath and some people are contagious despite never experiencing symptoms. But as the virus continues to spread, less common symptoms are being reported, including loss of smell, vomiting and diarrhea, along with a variety of skin problems and harmful neurological effects.

A recentreportfromDr. Robert Stevens, M.D., the associate director of the Johns Hopkins Precision Medicine Center of Excellence for Neurocritical Care, said that coronavirus patients are continuously experiencing a wide range of disconcerting effects on the brain.

Some of the neural symptoms, according to Johns Hopkins, include:

Patients are also having peripheral nerve issues, such as Guillain-Barr syndrome, which can lead to paralysis and respiratory failure, wrote Stevens. I estimate that at least half of the patients Im seeing in the COVID-19 units have neurological symptoms.

While medical experts have continuously repeated that more is still being discovered about the virus, Stevens listed some possibilities on how COVID-19, a respiratory illness, is making its way to the brain.

The first possible way is that the virus may have the capacity to enter the brain and cause a severe and sudden infection. Cases reported in China and Japan found the viruss genetic material in spinal fluid, and a case in Florida found viral particles in brain cells, Stevens wrote.

He added that viral particles in the brain and spine may occur when the virus enters the body through a patients bloodstream or nerve endings.

The second possibility is that the bodys immune system has an overreaction to the virus, causing severe inflammatory responses that cause organ and tissue damage.

The third theory is the erratic physiological changes the disease causes in the body, which involve extremely high fever and low oxygen levels in the blood, result in harmful effects to the brain.

Stevens added that there has been an abnormal observance of blood clotting that has caused some coronavirus patients to suffer strokes. A stroke could occur if a blood clot were to block or narrow arteries leading to the brain, he said.

Another illness that has been known to impact the brain in patients with COVID-19 is currently being studied by Dr. Mady Hornig, an immunologist and professor of epidemiology at Columbia University.

Hornig said that Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an illness that has been found in patients who have recovered from coronaviruses such as SARS.

TheCenters for Disease Control and Preventioncites a 2015 report from the nations top medical advisory body, the Institute of Medicine, which says that an estimated 836,000 to 2.5 million Americans suffer from ME/CFS.

The CDC says that people with ME/CFS experience severe fatigue, sleep problems, as well as difficulty with thinking and concentrating while experiencing pain and dizziness.

Hornig said SARS-CoV-1 and MERS have been associated with longer-term difficulties, in which many people appeared to have symptoms of ME/CFS.

Hornig is currently researching the long-term effects of COVID-19, and has been confronted with an array of concerning symptoms that have persisted in patients, as well as herself.

She can personally attest to the variety of symptoms that have been reported in coronavirus patients, ever since she began to experience her own COVID-19 symptoms in April that have continued to impact her daily life for the past few months.

She has also experienced cardiac complications while dealing with the illness.

Since getting sick, Hornig said shes had to carry a pulse oximeter with her, a device which registers her pulse since she began to have tachycardia episodes when her fever began to decline. Tachycardia is a condition that can make a persons heart beat abnormally fast, reducing blood flow to the rest of the body,according to the Mayo Clinic.

Hornigs most recent episode was on June 22. Her pulse registered at 135 beats per minute, which she said occurred just from her sitting at her computer. She said a normal pulse for someone her age would be around 60-70 beats per minute.

The findings on the novel virus potential effects on the heart and brain come as the CDC continues to update itslistof coronavirus symptoms and high-risk conditions for COVID-19 complications.

Notably, the CDC also removed the specific age threshold from the older adult classification. CDC now warns that among adults, risk increases steadily as you age, and its not just those over the age of 65 who are at increased risk for severe illness, the agency wrote.

Johns Hopkins has noted that younger patients in their 30s and 40s are reportedly having strokes as a result of COVID-19.

It may have something to do with the hyperactive blood-clotting system in these patients, Stevens said. Another system that is hyper-activated in patients with COVID-19 is the endothelial system, which consists of the cells that form the barrier between blood vessels and body tissue. This system is more biologically active in younger patients, and the combination of hyperactive endothelial and blood-clotting systems puts these patients at a major risk for developing blood clots.

But Stevens cautioned that more conclusive data is needed before the medical community can say with assurance that younger people are particularly susceptible to strokes caused by the novel coronavirus.

It is also plausible that theres an increase in stroke in COVID-19 patients of all ages, Stevens said.

34.052234 -118.243685

View post:
Its not just the lungs: COVID-19 can affect the brain and heart of those infected, researchers say - WITI FOX 6 Milwaukee

Inequality in COVID-19 Has Other Dangerous Consequences – Fox and Hounds Daily

Tanya Klowden is a physicist with a background in design and history whose work is focused on identifying the works and telling the stories of unrecognized and underappreciated artists and voices in history.

Over the past several weeks, the outcries over the killing of George Floyd in Minneapolis, combined with recent killings of Ahmaud Arbery in Brunswick, Georgia and Breonna Taylor in Louisville, Kentucky have grown to a dull roar, finally focusing our nation on the tremendous risk of violence and death borne on a daily basis by people of color within this country. As our broader population has begun to address the widespread and persistent violence that has plagued minority communities for generations, medical researchers in the past few weeks have expressed significant concern over another urgent threat, finding a much higher death rate from COVID-19 within our African-American communities here in California and in the country as a whole.

We have observed over the past several weeks what we already knew, or at least should have known, that disease falls hardest on the most underprivileged and that minorities in particular, independent of their economic status, are at a higher risk of death. The non-partisan APM research lab released figures showing that African-Americans have died from COVID-19 alone at a rate of 50.3 per 100,000 people- well over twice the rates for whites (20.7), Latinos (22.9) and Asian Americans (22.7). There are several reasons for this, none of which is biological susceptibility. Most of the difficulties are direct impacts of systematic racism, so it is important we look at some of these issues to better understand why they are amplifying, rather than suppressing, the impact of disease.

In fact, per capita public health spending (and public education spending) is measurably lower in most regions in this country with a significantly higher African-American population. While lower public health spending in your region will result in poorer outcomes all by itself, medical professionals find that they are also struggling with high levels of distrust from minorities, particularly from those in the older generations. The more privileged you are, the less likely you are to have ever been treated by, and simultaneously not trusted, your doctor. As a privileged person, you probably learned about the Hippocratic oath at a young age and always accepted that your doctor made a promise to help, not harm, in all circumstances.

To help place you in the mindset of someone who has been given no reason to trust doctors and every reason to fear them, I have for you the story of Henrietta Lacks. Henrietta Lacks was an African-American woman born in 1920. She worked as a tobacco farmer and was a mother from an early age. When she was thirty, after giving birth and hemorrhaging severely after, she was diagnosed with cervical cancer. She was given routine (at the time) treatment for her cancer and instructed to follow up with the hospital. During followup treatment she was admitted to the hospital at her request due to severe abdominal pain and remained hospitalized until her death two months later, in 1951.

For a very long time, that seemed to be the end of Henrietta Lacks story. What is both remarkable and deeply problematic is that her contributions to society did not end at her death. Henrietta Lacks has saved your life and my life and she is absolutely on the front-line fighting against Covid-19 right now.

During her treatments, healthy and cancerous tissue was sampled from her body without her knowledge or consent. Those cells were cultured and displayed the unique ability to reproduce endlessly and remain alive within a culture for far longer than any previous cell lines medicine had studied. Anonymized simply as the HeLa cell line, they became the standard for human medical research; Henriettas bodyweight in cell mass being grown millions of times over (over 50 million metric tons as of 2011) to meet the insatiable needs of modern medicine. Without Henrietta Lacks, there would have been no California Stem Cell Initiative and no California Institute for Regenerative Medicine, among numerous efforts that have enabled the rise of biotechnology and life science research in the state.

Not only was Henrietta herself never able to give consent to this or any use, her family did not even know of the existence and tremendous spread of her genetic material until early in the 21st century, by which time HeLa usage was so widespread there was no ability to grant or withdraw consent. As of 2013, the only gain her family has secured from her legacy is a promise from the NIH of acknowledgement in subsequent scientific papers and two seats on a panel regulating access to her DNA sequence going forward. While Henrietta Lacks story is extraordinary, her treatment by the medical community is in many ways typical of the healthcare African Americans have experienced over the last 70 years, with African-American healthcare prior to that being literally the stuff of nightmares. Within the past century, there are plentiful accounts of forced sterilizations, of being placed in trials without their knowledge or consent, of being accused of lying when recounting their history or symptoms, of being lied to, and even of being straight-up experimented on as an expendable population. In light of this history, it becomes much clearer why many minority groups would push back when told to sacrifice their jobs to keep others healthy, to stay home when the grocery store shelves are emptying, to leave the hospital when a relative is struggling for breath with no way of knowing what will happen to their loved one inside the hospital doors once they are not there to watch over them.

When this is compounded by widespread suspicion of any African-American individual wearing a mask who walks their dog or goes to a market to shop, the significant risk of grave harm is only compounded further. While the loudest voices against masks have been those of angry white people upset at the disruption of their privilege, minorities are very aware that at the intersection of masks, profiling, and persons of color the health risks of mask wearing are very real. In recent weeks, we have already seen violence inflicted on African-Americans for looking suspicious by being in public while following CDC guidelines. In April, a succinct tweet circulated stating it bluntly. I dont want to die and on the other hand, I dont want to die. Jokes from the privileged about committing crimes, being nefarious, or shady need to stop. None of that does what is urgently needed, which is to normalize mask usage among all groups so that it can help slow the spread of disease. We can instead treat people of color within our communities with respect, and listen to their perspectives in navigating through this global health crisis.

The pain and death we are inflicting on the African-American community may be far more apparent now, but we need to recognize and address the fundamental wrongs that extend far beyond policing, and even healthcare. We are not going to fix this environment overnight, but we definitely do not need to make it worse. Right now our minority communities urgently need funding. Public health funding is absolutely critical but these communities also need funding to provide masks and other desperately needed protective equipment to every individual who must spend long hours working in public spaces, funding to keep people securely housed, with ample access to healthy food, funding for widespread, low-cost (or free) internet connectivity so that the poorest children within our society can continue to be educated through distance-learning alongside their more privileged peers. Looking further ahead, we desperately need to nurture a new generation of African-American scientists and doctors by reaching out to students early, while they are still in primary school, and we need to rebuild bridges to the community with better, more accessible and trusted healthcare. Weve already collectively inflicted plenty of harm, we can at least start to make steps towards making their situation better.

Facebook

Twitter

Linkedin

Pinterest

email

More here:
Inequality in COVID-19 Has Other Dangerous Consequences - Fox and Hounds Daily

Anniversary in the year of the coronavirus: 100 years of health protection at Audi – Automotive World

Good health is in higher demand than ever: Audi Health Protection is celebrating its 100th anniversary in 2020. Thanks to the coronavirus, there will be no big celebration. The coronavirus pandemic has once again demonstrated the central importance of our health, both in society and at companies. At Audi, the health of our employees is at the forefront of everything we do, says Chief HR Officer Sabine Maaen.

The first full-time paramedic started working at NSU, a predecessor of the four rings, in Neckarsulm in 1920, marking the birth of professional health protection at Audi. In the beginning, the focus was on caring for employees in the event of injuries or acute emergency situations. This aspect is still an essential element today. If something happens at the plant, for example if somebody has a heart attack, we usually arrive at the scene within three minutes. This proximity and speed of action helps to save lives, says Andreas Haller, Head of Audi Occupational Health. Health protection at the four rings now has many facets, ranging from acute and emergency medical attendance, preventative occupational health care, individual prevention, and the inclusion of employees who receive consultation on their job due to health-related limitations, and all the way to workplace design itself, which should be ergonomic, safe, and maintain the employees health. Most recently, we made the workstations at Audi coronavirus-ready, for example. We work very closely and very successfully with many partners in the company in this area, says Haller.

The Works Council is an important partner in this cooperation. Peter Mosch, Chairman of the General Works Council of AUDI AG: To us as the employee representation, accident prevention in the company and our colleagues health are very important. If you look back at the beginnings of industrial work including in the automotive industry and compare that with todays occupational safety standards, it is clear that things have come along way at both the company and political levels over the past 100 years. I am very grateful to all the members of the in-house occupational health protection committees on-site company doctors, managers, and members of the Works Council who are working together with great commitment to set a high standard for health protection at Audi.

What started out small in 1920 has evolved tremendously over the space of a century. Today, there are three Occupational Health Centers at the two Audi sites in Germany: one in Neckarsulm and two in Ingolstadt. More than 100 employees see to the wellbeing of their colleagues at Audi in Germany, but also at the international locations of the four rings, together with their medical colleagues on-site. In Belgium, Mexico, and Hungary, for example, there are separate branches for employee health protection. The range of services of Audi Occupational Health has also increased considerably in the course of the decades: Today, health protection comprises not only occupational health care and the prevention of work-related illnesses and occupational illnesses, company health and integration management, acute and emergency medical care but also individual preventive health. For example, the Audi Checkup was established in 2006:

The aim is to identify health risks early on, prevent chronic illnesses, and convey knowledge on health-conscious behavior. Roughly 90 percent of employees take advantage of this voluntary examination and preventive program regularly. Since the program started in 2006, more than 100,000 employees have take part, and more than 10,000 Audi employees went for a checkup in 2019 alone. The Audi Checkup is part of the works agreement on health, on the basis of which the company and Works Council have committed to maintaining, promoting, and restoring the physical and mental health of the employees.

Audi Health Protection doesnt just do what is expected but also goes the extra mile: for example with the current campaign Jeder hat Psyche. Why not talk about it?. This campaign has been in existence since last years World Mental Health Day (October 10). The project aims to promote a more natural approach to the topic of mental health and thereby contribute to destigmatizing mental illness. The employees involved in the project provide information at company events, hold their own information events, distribute flyers and other information material, and raise awareness about points of contact for Occupational Health, such as the established consultation hour on mental health or the consultation hour on addiction. The four rings have had offers relating to mental health for a long time, but it was the current campaign that provided many employees with an incentive to open up and talk more openly about their own issues or offer their help to affected colleagues.

Occupational Health also takes social responsibility, for example with its offering for employees to register with the worldwide database for the battle against leukemia during their working hours. Audi has been working with the relevant institutions in this field for many years and pays the laboratory costs for typing. As a result, there are numerous stem cell donors and thus lifesavers among the Audi employees.

Speaking of lifesavers: The Audi emergency paramedics are not there just for the Audi employees but also for the people who live at the locations. On the basis of corresponding agreements, they can also respond to emergencies outside of the plant gates. This is the case, for example, if the local rescue control center determines that the Audi emergency medical service is closer and can therefore get to the site of the accident more quickly than another emergency medical service. In 2019 alone, the Audi paramedics were called to more than 1,300 external emergencies to cover peak demand. Audi chief physician Haller says: We are happy to do our bit for our home regions here. At the same time, we benefit from these emergency responses as well: Our paramedics are always very well trained. As regards the Audi workforce, occupational physician Haller has one big goal: We want our employees to be fit and healthy when they start their well-deserved retirement after reaching retirement age.

SOURCE: Audi

Here is the original post:
Anniversary in the year of the coronavirus: 100 years of health protection at Audi - Automotive World

Five Year-old Boy with Covid-19 Saves Sisters Life in Thailand – Chiang Rai Times

Even though he had Covid-19, Sila Jio Boonklomjit, a five-year-old boy in Thailand, with covid-19 managed to save his sisters life. With the stem cells he donated for her bone marrow transplant.

Doctors only discovered Jio contracted the coronavirus the day before Jintanakan Jean Boonklomjit, his sisters urgent transplant.

Despite the challenges, which included quarantine restrictions placed on Jio on the eve of the transplant procedure. However the treatment was carried out successfully.

And it was done so without Jio passing the coronavirus to Jean.

While the experimental procedure first began in April, the bone marrow was only successfully transplanted on June23 at Ramathibodi Hospital.

Jeans case was believed to be the first successful stem cell transplant from a donor with active Covid-19, according to reports.

She was reported to be in a severe condition as she wasborn with thalassemia a genetic blood disorder that limits the bloods ability to carry oxygen.

There were also difficulties finding a suitable donor for Jean, which left Jio as their best hope, said Suradej Hongeng of the hospitals pediatrics department.

It was a long and uncertain road to this happy outcome, according to the doctor.

Jio and Jean were confirmed to be a genetic match in 2018. The hospital prepared for the transplantation procedure thereafter.

But with any medical procedures, there were certain complications and hurdles involved.

According to Suradej, the siblings young age were part of the difficulties faced during the procedure. Jeans chemotherapy procedure also caused her immune system to be compromised. That delayed the bone marrow transplant until this year.

Still, things turned out well in the end, and the five-year-old boy was applauded for saving his big sisters life.

Its as if my daughter is reborn and gets a new life, said the childrens father, Suchai Boonklomjit.

Jio has since recovered from Covid-19, which was believed to be transmitted from his mother, according to doctors in Thailand.

Thailands health department has reported on Monday that the Kingdom has gone 35 consecutive days without a local Covid-19 Coronavirus case. However health officials have confirmed 7 imported cases with Thai returnees.

The 7 imported covid-19 coronavirus cases brings the total number of infections in Thailand to 3,169 with 58 deaths since January. All the new cases were Thai nationals in quarantine. They recently returning from India and the US to Thailand.

There have been no local transmissions for 35 days Thailands health department said Monday.

Continue reading here:
Five Year-old Boy with Covid-19 Saves Sisters Life in Thailand - Chiang Rai Times

What causes joint pain and how to slow down their defeat. Responsible orthopedic trauma – The Saxon

Natalia SANDROVICH, FACTS

The trouble is, when people due to joint pain can not climb on a moving bus. Or when it is difficult to get out of bed to walk around the room, pour a Cup of tea, cut a slice of bread. The doctor who came in a direct line of FACTS orthopedist-traumatologist, head of the scientific Department of reparative and reconstructive orthopedics and rehabilitation center of innovative medical technologies of NAS of Ukraine, candidate of medical Sciences Eugene Skobenko, emphasizes: one should Never ignore the pain, thinking that it will go away. If the time to diagnosis and prescribe treatment, the affected joints can be braked. How to confirm the diagnosis of osteoarthritis and to treat this disease? Is it possible to move the surgery to replace the joint? What to do when you break the cords? To these and other questions from our readers answers in a straight line FACTS.

See also: How to get rid of knee pain: the advice of a doctor

* Hello, Evgeny! Are you worried about Irina from Kiev, 46. I was diagnosed with primary osteoarthritis of the knee. Why so early? Moms knees began to ache after 60 years.

Have osteoarthritis several reasons. In addition to hereditary predisposition, are important features of the anatomy. The knee joint wears more on the side which is stronger, as it happens, for example, when you have flat feet. Due to the deformity and malposition of the ankle joint and knee suffering. Osteoarthritis often occurs as a result of injury, for example, damage to the meniscus. Especially if it is incorrectly treated or removed.

* Is Oksana from the city of Kagarlyk of Kiev region. My husband (hes 51) long-standing gout. And now add another osteoarthritis. There are days when she can hardly walk even around the yard. These two diseases are somehow connected?

Yes, gout is like rheumatoid arthritis, causes the development of osteoarthritis. The people are of the opinion that the gout is an inflammation of the joint of the big toe. Actually gouty arthritis affects all the joints.

The basis of gout a metabolic disorders. Treatment involved rheumatology. In the patient accumulates a large amount of uric acid which is deposited crystals inside the joint.

* Calling Galina from Transcarpathia. Started to hurt my knees, and the doctor suspected osteoarthritis, sent for an MRI. They found fibrosis, synovitis. What to do?

In-depth examined. The fibrous tissue is formed in the area of overload of the joint, and may be due to the fact that in osteoarthritis the cartilage has become thin and lost its damping properties. Sometimes arthritis accompanies chronic inflammation (rheumatoid arthritis, chondroplasia).

It is important to find the cause of the inflammation of the synovial fluid. Normal her in the joint for about two to four milliliters, but because of the inflammatory process, the quantity increases. Excess fluid can be removed. However, if you do not establish a cause of synovitis (rheumatoid arthritis, inflammatory connective tissue diseases, Lyme disease), the fluid will appear again.

* Are you concerned about Valentina from Kiev, 80 years. I am absolutely healthy person, while lying on a hard orthopaedic mattress. As soon as I get up, immediately there is a sharp pain in the lower back radiating to the legs. When I disagree, pain is reduced. What to do?

The cause of the pain may be due to the instability of the spine in the lumbosacral region. It is necessary to be surveyed: to make MRT a lumbar Department of a backbone, and a functional x-ray sample.

While I take nonsteroidal anti-inflammatory drug. Is this correct?

Yes, but be careful. All painkillers nonsteroidal anti-inflammatory drugs increase the secretion of gastric juice. They need to drink after a meal or under the guise of drugs that slow the production of gastric juices and reduces the aggressive environment in the stomach. But uncontrolled nonsteroidal anti-inflammatory drugs can cause gastritis, stomach ulcers and even bleeding.

See also: the Joint can hurt and destroy because of the old injury, which people have forgotten, the doctor

* My name is Neal, Im calling from Kiev. Question for my sister, who is 72 years old. She had two strokes and surgery to replace the hip joint (a hip fracture). Now the sisters have a really sore foot and has difficulty walking, knee not bend, turned foot, heel touching the ground. How to help her?

I think the knee bend is not due to a lack of rehabilitation after strokes. Apparently, in the developed joint contractures limiting mobility. And what are the pain, you need to understand. They can be caused as defeats of the joints and spasticity involuntary muscle contractions resulting from disorders of cerebral circulation. Your sister needs help experts good rehabilitation center.

If one leg is shorter, it is desirable to select orthopedic shoes. To also fix the orthosis knee joint.

Causes of osteoarthritis

* Is a straight line? Calling Olga from the city of Irpin, Kyiv region, 51. Start whining to the knee, and examination revealed osteoarthritis of 2-3 degrees. How to treat this disease?

Tell, how we act. First, we examine the patient to get a correct history. Pain can be in the region of the knee joint, and in fact the affected hip. So often we take x-rays of the pelvis. Also check the lower back, where it can be a source of pain that radiates to the joint, for example, a small hernia in the lumbar. It compresses the nerve root, causing pain.

In addition to x-rays, sometimes MRI is assigned. It happens that the person suffers from severe pain, and x-ray changes are not showing. With the help of magnetic resonance imaging possible in the early stages to see circulatory disorders in the bone (called avascular necrosis).

In order to properly prescribe treatment, it is important to determine the degree of osteoarthritis. Increasingly widely used cell therapy, using plasma and stem cells. In the first case, taking blood from a vein and in a special vial to be processed using a centrifuge, separating the upper layer of plasma containing cells and growth factors. Cells work as building material, and growth factors triggers the repair their own tissues.

Even more effective in the early stages of the disease, injection of stem cells into the joint. Through punctures recruited from the abdomen or thighs of the patient fat, as do plastic surgeons for liposuction, processed and secreted from stem cells. 30 milliliters of fat we get about four ounces of finished cellular substance.

See also: the Knee I had cured, using a cocktail of my own stem cells and blood plasma

* It refers you to Tamara from Kiev, age 79. By arthritis very sore big toe. Will the injections of hyaluronic acid? Previously, I did them in the knee, and the pain was gone.

Alas, for the small joints of the foot, this treatment can be ineffective. It is often used for joints carrying axial load: knee, hip, ankle. But if they change the deep, the hyaluronic acid is also ineffective.

How then to ease the pain?

With the help of physiotherapy, orthotics or surgery. The insole can be purchased in orthopedic stores or available individually. And to make other appointments, you need to see your x-rays. Can contact our Center for innovative medical technologies (Kyiv, descent Voznesensky, 22). Pre-call by phones: (044) 272-22-05 or (044) 272-34-03.

* Could I speak to the doctor? Taras from Lviv, 54. Due to old injuries I have pronounced osteoarthritis of the knee. Bad leg flexion and extension: contracture of more than 40 years. I read that sometimes replacing the joint completely, and only his head set so-called cap prosthesis. Is this possible?

Only if you allow the bone quality and the degree of osteoarthritis. You have a contracture, which will complicate the work of the surgeon, impede the development of the feet. A complete total prosthesis, which was adopted worldwide, will provide an opportunity after recovery to move normally.

Im afraid that changes the length of the legs of my friend.

Sometimes leg really extended or shortened, as we will warn patients. So there are no surprises, for surgery you need to prepare carefully, not only the doctor but the patient. You can not go to intervene, not cure, for example, rotten tooth. Any infection can harm implants, because it is, in fact, the weak link in the body.

What studies clarify the diagnosis

* The FACTS? Worried about Alexander from Odessa, 50 years. I have a few years ago, discovered the trichinosis parasitic infection. After the treatment complications at the joints of the legs: they occasionally get sick, especially in the morning. How to avoid further deterioration?

To answer your question, you need to clearly understand what kind of complication you have experienced after the treatment. You should monitor the condition of the joints using x-rays, MRI. To support the hyaluronic acid preparations, which are prescribed by a doctor. It creates in the joint of the gel layer that reduces the blurring of the cartilage and improves glide in the joint.

But General recommendations are reduced to a few simple rules. It is impossible to gain weight, overloading the joints. To maintain the condition of the cartilage of funds to help with substances, life-prolonging cartilage, warning her wear chondroitin, glucosamine and collagen.

It is important to drink plenty of fluids, because cartilage consists mostly of water. It is also advisable to avoid heavy physical exertion, trauma. Try to lead a healthy lifestyle. Any systemic diseases, such as diabetes, can lead to deterioration of health.

* Is a straight line? Calling Maria from the city of Ternopil. Son played football and has damaged the anterior cruciate ligament. Inflammation doctors removed, but insist on surgery. Is it necessary?

Yes. Plastic anterior cruciate ligament the most common operation that I have to do on the knee joint. Without it, an unstable joint is not resistant to excessive load. People will not be able to run, squat, even to play beach volleyball. And most importantly later he faces early osteoarthritis.

See also: how to avoid flat feet, the child need to not go barefoot, doctor

How to perform such operations?

With the help of the arthroscope through a small puncture go into the joint, evaluated the damage. If the ligament is completely torn, most often carried out plastic model with tendons taken from the adductor muscles of the thigh.

* Inna from the city of Khmelnitsky. After surgery for cruciate ligament rupture husband of six months wore a brace. How to recover?

A rehabilitation plan is specialist. It depends a lot on equipment operation and related damage in the joint. I often, for example, recommend a week on crutches, another doctor may prescribe them for up to two weeks, or will think that you can do without them. It all depends on the damage in the joint. If, for example, a torn meniscus, it is necessary to save, because it takes some of the load, acts as a shock absorber and stabilizer. Removing it we increase the risk of developing osteoarthritis. It is important to know that not all gaps can be made.

The knee of the patient record for three weeks in a special brace. In a week you need to begin to develop the joint to bend and straighten the knee, and after a month and a half to do spinning and swimming. After three months, you can train the muscles in the gym, because the quadriceps thigh muscle atrophies greatly. When the six months are allowed to play sports.

How to help my joints

Previously, the orthopedic trauma Yuri Poroshenko told, what mistakes in the treatment of trauma interfere with recovery

Photo of Igor EMELYANENKO, FACTS

More:
What causes joint pain and how to slow down their defeat. Responsible orthopedic trauma - The Saxon